Physician profile
Ryan Maenpa
NPI 1871571760
$3,905.60
in general payments reported to CMS, 2019-2025
42 companies · $645 in 2025
The $645 reported for 2025 was more than what 82% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $530 · 2020: $166 · 2021: $789 · 2022: $693 · 2023: $400 · 2024: $683 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,727.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $607.46 | 2019-2025 | |
| Emd Serono, INC. | $528.65 | 2021-2025 | Mavenclad |
| Amgen INC. | $245.79 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $214.80 | 2019-2025 | Rytary, Crexont, Lyvispah |
| Biogen, INC. | $162.55 | 2019-2025 | Vumerity |
| Ucb, INC. | $153.17 | 2021-2025 | Briviact, Zilbrysq, Nayzilam |
| Biohaven Pharmaceuticals, INC. | $146.45 | 2021 | |
| Alexion Pharmaceuticals, INC. | $142.19 | 2019-2025 | Soliris, Ultomiris |
| Acadia Pharmaceuticals INC | $131.06 | 2022-2025 | Nuplazid |
| Eisai INC. | $120.58 | 2019-2024 | |
| Sk Life Science, INC. | $103.76 | 2021-2024 | |
| Lilly USA, LLC | $99.88 | 2019-2024 | Kisunla, Amyvid, Emgality |
| Sunovion Pharmaceuticals INC. | $95.41 | 2019-2021 | |
| Mdd US Operations, LLC | $95.35 | 2019-2024 | Gocovri |
| Acorda Therapeutics, INC | $93.28 | 2019-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Maenpa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.